🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Tata Memorial Hospital clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our India register with Tata Memorial Hospital as lead sponsor. Synced 26 Sep 2026
24Current trials
18Recruiting now
5Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Tata Memorial Hospital is the lead sponsor of 24 current clinical trials in our India register. 18 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Capecitabine, Carboplatin and Cisplatin. The most-studied condition is Cervix Cancer.

ClinicalTrials.gov trials by status

  • Recruiting1875%
  • Active, closed625%

Trials by phase

  • Observational1042%
  • Phase 3521%
  • Not applicable521%
  • Phase 228%
  • Phase 2/314%
  • Phase 114%
01

Clinical trials sponsored by Tata Memorial Hospital

24 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Clinical Outcomes and Quality of Life in Patients With Locally Advanced Vulvovaginal Cancers: Ambispective Registration Study.
NCT07179757 · Vulvo-vaginal Cancer
Observational Recruiting 2021-10 India
FAPi PET in Pancreatic Ductal Adenocarcinoma
NCT07342231 · Pancreatic Cancer, Adenocarcinoma Pancreas
Observational Recruiting 2025-01 India
Late Radiation Toxicities in Cervical and Endometrial Cancer: A Postoperative IMRT/Brachytherapy Study
NCT07435623 · Endometrial Cancer, Cervix Cancer
Observational Recruiting 2025-05 India
Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC
NCT05278052 · ClinicalTrials.gov ↗ · Oligometastatic Disease, Metastatic Non Small Cell Lung Cancer
Phase 3 Recruiting 2020-04 India
Compliance to Cervical Cancer Chemoradiation Guidelines: A Multicentric Implementation Audit and Resource Assessment Initiative of National Cancer Grid of India
NCT07290972 · ClinicalTrials.gov ↗ · Cervical Cancer Screening, Gynecologic Cancers, Treatment Compliance
Observational Recruiting 2021-02 India
Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocrine Tumors
NCT07404176 · ClinicalTrials.gov ↗ · Neuroendocrine Neoplasms (Tumours), Neuroendocrine Tumors, Metastatic Neuroendocrine Tumors
Phase 2 Recruiting 2026-03 India
Spatially Fractionated Radiation Treatment for Gynaecological Cancers
NCT06644846 · ClinicalTrials.gov ↗ · Cervical Cancer, Gynecologic Cancer, Recurrent Cancer
Not applicable Recruiting 2024-10 India
A Prospective Evaluation of the Peri-operative Hypoxia in Breast Cancer
NCT03797482 · ClinicalTrials.gov ↗ · Breast Cancer Female
Observational Recruiting 2017-11 India
Development of Clinically High Efficient Platforms for Individualised Treatment of Cervix Cancer
NCT05102240 · ClinicalTrials.gov ↗ · Cervix Cancer
Observational Recruiting 2022-02 India
PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)
NCT07185672 · ClinicalTrials.gov ↗ · Neuroendocrine Neoplasia's (NENs), Neuroendocrine Tumor GEP Grade 1-3, Neuroendocrine Gastroenteropancreatic Tumour
Phase 3 Recruiting 2019-08 India
Palliative Radiation for Advanced Cervical Cancer
NCT03997110 · ClinicalTrials.gov ↗ · Cervical Cancer
Not applicable Recruiting 2020-06 India
Cervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study.
NCT07400809 · ClinicalTrials.gov ↗ · Chemotherapy, Treatment Compliance, Radiotherapy
Observational Recruiting 2023-08 India
Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma.
NCT02964858 · ClinicalTrials.gov ↗ · NonHodgkin Lymphoma
Not applicable Recruiting 2016-11 India
Systemic and Tumor Immune Response During Pelvic (Chemo)Radiation and/or Brachytherapy for Cervical Cancer
NCT06804135 · ClinicalTrials.gov ↗ · Cervical Carcinoma
Observational Recruiting 2025-10 India
Asian Gynecological Brachytherapy Registry in Cervical Cancer
NCT07196033 · ClinicalTrials.gov ↗ · Stage IIIA Cervical Cancer FIGO 2018, Stage IIIB Cervical Cancer FIGO 2018, Stage IVA Cervical Cancer FIGO 2018
Observational Recruiting 2026-02 India
Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC
NCT05277844 · ClinicalTrials.gov ↗ · Oligometastatic Disease, Non-small Cell Lung Cancer, Driver Mutation
Phase 2 Recruiting 2019-11 India
Sentinel Node Biopsy Versus Limited Elective Neck Dissection in Early Cancers of Oral Cavity NoDe Negative
NCT05774483 · ClinicalTrials.gov ↗ · Mouth Neoplasms, Oral Cancers, Oral Squamous Cell Carcinoma (OSCC)
Not applicable Recruiting 2025-04 India
Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT
NCT05236946 · ClinicalTrials.gov ↗ · Asymptomatic Brain Metastases, Driver Mutation Positive Non-small Cell Lung Cancer
Phase 3 Recruiting 2020-11 India
Perioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers
NCT02867865 · Gall Bladder Cancers
Phase 2/3 Active, closed 2016-09 India
To Check Safety of Ayurvedic Oral Cannabis in Breast and Head and Neck Cancer
NCT05969314 · Breast Cancer, Oral Cancer
Phase 1 Active, closed 2022-06 India
Impact of Molecular Pathological And Clinical Features for Adjuvant Treatment Selection in Endometrial Cancer: Asian Registry
NCT07354087 · Endometrial Cancer
Observational Active, closed 2024-11 India
A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer
NCT03168880 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer
Phase 3 Active, closed 2010-04 India
Randomized Controlled Trial to Assess Blockade of Voltage Gated Sodium Channels During Surgery in Operable Breast Cancer
NCT01916317 · ClinicalTrials.gov ↗ · Operable Breast Cancer
Phase 3 Active, closed 2011-12 India
Randomized Controlled Trial Evaluating the Role of Exercise in Women Undergoing Treatment for Breast Cancer
NCT02161900 · ClinicalTrials.gov ↗ · Non Metastatic Operable Breast Cancer
Not applicable Active, closed 2010-11 India

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Tata Memorial Hospital trials

5 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Tata Memorial Hospital trials

43 conditions
Cervix Cancer3Endometrial Cancer2Oligometastatic Disease2Treatment Compliance2Cervical Cancer2Vulvo-vaginal Cancer1Pancreatic Cancer1Adenocarcinoma Pancreas1Gall Bladder Cancers1Breast Cancer1Oral Cancer1Metastatic Non Small Cell Lung Cancer1Cervical Cancer Screening1Gynecologic Cancers1Chemoradiotherapy1Neuroendocrine Neoplasms (Tumours)1Neuroendocrine Tumors1Metastatic Neuroendocrine Tumors1Gynecologic Cancer1Recurrent Cancer1Breast Cancer Female1Triple Negative Breast Cancer1Operable Breast Cancer1Neuroendocrine Neoplasia's (NENs)1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in India2418

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Cervix Cancer

SponsorTrials
Ding Ma1

Sponsors with the most current trials registered for this condition.

06

Questions about Tata Memorial Hospital trials

How many clinical trials does Tata Memorial Hospital sponsor?

Tata Memorial Hospital is the lead sponsor of 24 current trials on ClinicalTrials.gov in our India register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Tata Memorial Hospital trials recruiting?

Yes. 18 of its 24 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Tata Memorial Hospital testing?

Its current trials name 5 drugs and biologicals as interventions. The most frequent are Capecitabine (1), Carboplatin (1), Cisplatin (1), Gemcitabine (1) and Paclitaxel (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.